Mezagitamab
Based on 1 publication(s) in Google Scholar
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
For research use only. We do not sell to patients.
- Purity : 99.76%
- CAS No.: 2227490-52-8
- Molecular Weight:143.7 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
CD38
In Vitro
Mezagitamab binds to CD38, allosterically inhibits the enzymatic activity of CD38, induces apoptosis by antibody-dependent cellular cytotoxicity (ADCC, activates immune cells such as NK cells) and complement-dependent cytotoxicity (CDC, activates the complement system)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[4]
-
Dosage:0.03-100 mg/kg
-
Administration:iv, once or twice a week for 4-13 weeks
-
Result:Reduced numbers of NK/B/T cells.
-
Animal Model:Collagen-induced arthritis in cynomolgus monkey models[4]
-
Dosage:3 mg/kg
-
Administration:iv,once weekly for 8 weeks
-
Result:Inhibited the progression of arthritis.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD38 Protein, Human can bind Mezagitamab. The EC50 for this effect is 61.97 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Mezagitamab (anti-CD38) (HY-P99730). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda1 (HY-P99992). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 2227490-52-8
-
Accession P28907
-
Synonyms TAK-079
-
Molecular Weight 143.7 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.76%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
[2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. [Content Brief]
[3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. [Content Brief]
[4]. Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402. [Content Brief]
[5]. Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)